Navigation Links
National Brain Tumor Society Responds to Results of Avastin Clinical Trials

Boston, MA (PRWEB) June 03, 2013

National Brain Tumor Society, the largest nonprofit in the United States dedicated to the brain tumor community, issues the following statement regarding clinical trial results involving the cancer drug Avastin reported at the American Society of Clinical Oncology’s 2013 Annual Meeting:

"Beginning in May of 2009, drug maker Genentech received accelerated approval from the U.S. Food and Drug Administration (FDA) to market Avastin (bevacizumab) for the treatment of recurrent glioblastoma multiforme (GBM). National Brain Tumor Society has since followed the progress of Genentech’s required post-market study of Avastin called AVAglio, and has also sought input from the brain tumor community about the role Avastin has played as one of only four approved brain cancer drugs.

National Brain Tumor Society is deeply disappointed in the recently announced results of the AVAglio clinical trial. This trial revealed that Avastin (in combination with standard of care treatments) did not significantly prolong the lives of newly diagnosed GBM patients.

We are equally concerned with additional findings from a large, National Cancer Institute (NCI)-supported clinical trial conducted by the Radiation Therapy Oncology Group (RTOG). Similar to the AVAglio trial, the RTOG study did not show statistically significant increases in overall survival for newly diagnosed GBM patients taking Avastin in combination with standard of care treatments. Data from the AVAglio and RTOG studies collectively have provided mixed results on issues such as progression-free survival (i.e. a measure of tumor growth in response to a therapy) and quality of life, which will require careful and further analysis to better understand their full meaning in terms of patient care.

Avastin is an important part of the current limited treatment landscape for many brain cancer patients. National Brain Tumor Society understands that Avastin has helped some brain cancer patients have a higher quality of life in their last months, and as such we think it is important that it remains an available treatment option for patients and doctors.

While we had hoped to see positive overall survival figures, the gold standard of measurement for oncology drugs, further analysis of the recently concluded trials, as well as an anticipated FDA reaction, will necessitate larger discussions about Avastin’s role as a brain cancer treatment. Most important for patients, Avastin is still approved as a treatment for recurrent GBM.

The discouraging results from the AVAglio and RTOG studies underscore the critical importance of advancing research for the discovery of new, more durable therapies, while advocating for the continued availability of all treatment options for brain tumor patients.

Going forward, the National Brain Tumor Society will work with our medical and scientific advisors to bring clarity to the issue of how Avastin and other targeted therapies fit into the current brain tumor treatment standard. Additionally, we are steadfastly determined to support the development of new therapeutic approaches through our integrated research and public policy programs.

Brain cancer is one of the most deadly and complex forms of all cancers. There are no known causes, no prevention methods, and few treatment options. National Brain Tumor Society is fiercely committed to continuing the fight to find effective, durable treatments and one day a cure."

About National Brain Tumor Society
National Brain Tumor Society is the largest nonprofit organization dedicated to the brain tumor community in the United States. We are fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means aggressively driving strategic research and advocating for public policies, which meet the critical needs of this community. To learn more visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
3. International Attendance for Networking and Education at Informex Beyond Manufacturing
4. Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
7. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
8. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
9. PAREXEL International to Present at J.P. Morgan Healthcare Conference
10. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
11. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform:
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use ... promoted Melanie Aregger to serve as Chief Operating Officer. , Having joined ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/10/2015)... About signature verification Signature ... identify and verify the identity of an individual ... secure and accurate method of authentication and is ... because each individual,s signature is highly unique. Signature ... signature of an individual is compared and matched ...
Breaking Biology News(10 mins):